Nkarta (NKTX) Liabilities and Shareholders Equity (2019 - 2026)

Nkarta's (NKTX) quarterly Liabilities and Shareholders Equity came in at $372.1 million in Q1 2026, down 20.94% year-on-year from $470.6 million in Q1 2025, and down 7.95% quarter-over-quarter from $404.2 million in Q4 2025.

Nkarta (NKTX) Liabilities and Shareholders Equity (2019 - 2026) Analysis & Trends

Nkarta's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $372.1 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 20.94% year-over-year to $372.1 million in Q1 2026; TTM through Mar 2026 was $1.7 billion, a 19.73% decrease from a year earlier, with the FY2025 full-year figure at $404.2 million, down 19.35% from the prior year.
  • Liabilities and Shareholders Equity retreated to $372.1 million in Q1 2026 per NKTX's latest filing, from $404.2 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $576.9 million in Q1 2024 and bottomed at $306.3 million in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $458.2 million (2023), against an average of $455.6 million.
  • Across the five-year window, Liabilities and Shareholders Equity jumped 72.67% in 2022 and fell 20.94% in 2026, its largest moves.
  • Year by year, Liabilities and Shareholders Equity stood at $472.9 million in 2022, then dropped by 19.89% to $378.9 million in 2023, then surged by 32.28% to $501.2 million in 2024, then retreated by 19.35% to $404.2 million in 2025, then slipped by 7.95% to $372.1 million in 2026.
  • Per Business Quant, the three latest NKTX Liabilities and Shareholders Equity figures stand at $372.1 million (Q1 2026), $404.2 million (Q4 2025), and $427.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 311.58 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 78.88 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 8.55 Bn
4 NuCana 279.75 Bn 279.75 Bn - 39.68 Mn
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 26.48 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 40.87 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - 811.27 Mn
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 10.03 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 2.25 Bn
10 Nkarta 170.79 Mn 170.79 Mn - 372.07 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 372.07 Mn
Dec 31, 2025 404.21 Mn
Sep 30, 2025 427.24 Mn
Jun 30, 2025 448.31 Mn
Mar 31, 2025 470.61 Mn
Dec 31, 2024 501.20 Mn
Sep 30, 2024 532.03 Mn
Jun 30, 2024 554.09 Mn
Mar 31, 2024 576.94 Mn
Dec 31, 2023 378.89 Mn
Sep 30, 2023 405.86 Mn
Jun 30, 2023 429.04 Mn
Mar 31, 2023 458.17 Mn
Dec 31, 2022 472.94 Mn
Sep 30, 2022 503.80 Mn
Jun 30, 2022 503.64 Mn
Mar 31, 2022 306.30 Mn
Dec 31, 2021 273.90 Mn
Sep 30, 2021 292.47 Mn
Jun 30, 2021 309.11 Mn